Shots:

• The approval is based on the study assessing the effectiveness and safety of Ryplazim (every two to four days for 48 wks.) in 15 adult and pediatric patients with plasminogen deficiency type 1
• The therapy showed at least 50% improvement in lesions in 11 patients with lesions at baseline and absence of recurrent or new lesions in any of the 15 patients via 48 wks. treatment
• The therapy has received FDA’s ODD & application also received FTD- PR- and a Rare Pediatric Disease Priority Review Voucher. The PRV can be redeemed to receive PR for any subsequent marketing application or sold or transferred to other companies for their programs

  | Ref: PR Newswire | Image: CNW Group